Donna Lorntz, NP
Family · Fort Wayne, INNPI 1144589409
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,023, 2.8 times the $368 reported in 2021.
Across 154 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$644
- Novo Nordisk$400
- Medical Device Business Services, Inc.$221
- Lilly USA, LLC$188
- Abbott$167
- Antares Pharma, Inc.$167
- plus $1K from 17 others
What the payments were for
- Food & beverage$2,62992%
- Education$2328%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 41 | $644 |
| Novo Nordisk | 29 | $400 |
| Medical Device Business Services, Inc. | 4 | $221 |
| Lilly USA, LLC | 10 | $188 |
| Abbott | 3 | $167 |
| Antares Pharma, Inc. | 10 | $167 |
| AstraZeneca(2 entities) | 7 | $150 |
| Xeris Pharmaceuticals, Inc. | 7 | $144 |
| Tandem Diabetes Care, Inc. | 9 | $114 |
| Tolmar, Inc. | 6 | $95 |
| Neurocrine Biosciences, Inc. | 3 | $78 |
| Halozyme Inc | 4 | $73 |
| Pfizer | 4 | $72 |
| Recordati_rare_diseases_inc. | 3 | $71 |
| Boehringer Ingelheim | 3 | $65 |
| Astellas Pharma US Inc | 2 | $51 |
| BETA Bionics, Inc. | 2 | $40 |
| Sequel Med Tech, LLC | 2 | $34 |
| AbbVie | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| IBSA Pharma Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Lifescan, Inc. | 1 | $14 |
How this compares
$2,861 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone Cypionate | 17 | $598 |
Paid to pharmacies, not to this prescriber.
Other family in Fort Wayne
- Justin BrownFort Wayne$142K
- Tracy JohnsonFort Wayne$68K
- Grant BlauveltFort Wayne$28K
- Benjamin GiarmoFort Wayne$21K
- Katarzyna SedlaczekFort Wayne$20K
- Brandy DantzerFort Wayne$18K
- Catherine RobertsFort Wayne$13K
- Adam ZuberFort Wayne$13K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.